Get started
Recursion Pharmaceuticals, Inc.Recursion Pharmaceuticals, Inc.Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RXRX chart


Full chart

RXRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.36 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.53 USD
Net income (FY)
‪−328.07 M‬ USD
Revenue (FY)
‪44.58 M‬ USD
Shares float
‪323.88 M‬
Beta (1Y)
2.92

About Recursion Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Chistopher C. Gibson
Website
recursion.com
Headquarters
Salt Lake City
Founded
2013
FIGI
BBG00PQ4XJ45
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RXRX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RXRX is 6.03 USD — it has decreased by −0.99% in the past 24 hours. Watch Recursion Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Recursion Pharmaceuticals, Inc. stocks are traded under the ticker RXRX.
RXRX stock has fallen by −15.19% compared to the previous week, the month change is a −4.29% fall, over the last year Recursion Pharmaceuticals, Inc. has showed a −38.53% decrease.
We've gathered analysts' opinions on Recursion Pharmaceuticals, Inc. future price: according to them, RXRX price has a max estimate of 12.00 USD and a min estimate of 6.00 USD. Watch RXRX chart and read a more detailed Recursion Pharmaceuticals, Inc. stock forecast: see what analysts think of Recursion Pharmaceuticals, Inc. and suggest that you do with its stocks.
RXRX reached its all-time high on Jul 13, 2021 with the price of 42.81 USD, and its all-time low was 4.54 USD and was reached on May 2, 2023. View more price dynamics on RXRX chart.
See other stocks reaching their highest and lowest prices.
RXRX stock is 4.55% volatile and has beta coefficient of 2.92. Track Recursion Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Recursion Pharmaceuticals, Inc. there?
Today Recursion Pharmaceuticals, Inc. has the market capitalization of ‪2.36 B‬, it has decreased by −5.94% over the last week.
Yes, you can track Recursion Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Recursion Pharmaceuticals, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
RXRX earnings for the last quarter are −0.34 USD per share, whereas the estimation was −0.33 USD resulting in a −2.15% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about Recursion Pharmaceuticals, Inc. earnings.
Recursion Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪26.08 M‬ USD, despite the estimated figure of ‪18.72 M‬ USD. In the next quarter, revenue is expected to reach ‪12.19 M‬ USD.
RXRX net income for the last quarter is ‪−95.84 M‬ USD, while the quarter before that showed ‪−97.54 M‬ USD of net income which accounts for 1.74% change. Track more Recursion Pharmaceuticals, Inc. financial stats to get the full picture.
No, RXRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Recursion Pharmaceuticals, Inc. EBITDA is ‪−365.25 M‬ USD, and current EBITDA margin is −712.50%. See more stats in Recursion Pharmaceuticals, Inc. financial statements.
Like other stocks, RXRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Recursion Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Recursion Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Recursion Pharmaceuticals, Inc. stock shows the sell signal. See more of Recursion Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.